RxDoctor Payments Data

Roel Laygo, MD

Internal Medicine · Savannah, GANPI 1265471122

Payments from drug & device makers

$10,627in general payments, 2019–2025

Across 690 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Amgen$1K
  • Pfizer$849
  • Novartis$531
  • Lilly USA, LLC$501
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$10,612100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,627 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$116,585
Medicare patients
293
Services billed
1,459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide179$237,312
MounjaroTirzepatide86$123,253
JardianceEmpagliflozin78$95,933
EliquisApixaban97$95,822
FarxigaDapagliflozin Propanediol50$65,748
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$45,685
Repatha SureclickEvolocumab46$40,743
TradjentaLinagliptin40$35,902
TrulicityDulaglutide20$33,635
RexultiBrexpiprazole14$30,904
JanuviaSitagliptin Phosphate16$20,347
Tresiba Flextouch U-200Insulin Degludec29$17,155
NexletolBempedoic Acid21$13,764
BelsomraSuvorexant28$12,394
Tresiba Flextouch U-100Insulin Degludec21$10,502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,262$237,312179 claims
Lilly USA, LLCMounjaro, Trulicity$501$156,889106 claims
Boehringer IngelheimJardiance, Tradjenta$390$131,834118 claims
PfizerEliquis$849$95,82297 claims
AstraZenecaFarxiga$369$65,74850 claims
GSKTrelegy Ellipta$97$45,68531 claims
MerckJanuvia, Belsomra$148$32,74044 claims
Otsuka America Pharmaceutical, Inc.Rexulti$206$30,90414 claims
Esperion Therapeutics, Inc.Nexletol$290$13,76421 claims
Johnson & JohnsonXarelto$268$8,92713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →